In this study, 32 cases of T-cell lymphoma of angioimmunoblastic lymphadenopathy type (AILD-TCL) were investigated for their association with Epstein-Barr virus (EBV). For this purpose, three different approaches were applied: polymerase chain reaction (PCR) for the presence of EBV-DNA, in situ hybridization (ISH) for EBV-encoded small nuclear RNAs (EBER), and immunohistology for EBV-encoded latent membrane protein (LMP). PCR and EBER-ISH produced almost identical results, showing that all but one case of AILD-TCL contained EBV genomes. Three distinctive patterns of EBV infection were observed after immunophenotypical characterization of EBER-positive cells: (1) in 26% of the cases, B and T cells were infected, the majority of which were B cells of immunoblastic morphology located in the remnants of lym-N THE EARLY 1970s, several investigators described a I disease entity in patients presenting with generalized lymphadenopathy, hepatosplenomegaly, hypergammaglobulinemia, hemolytic anemia, and other autoimmune phenomena. Histologically, the lymph nodes were characterized by a proliferation of medium-sized to large immunoblast-like lymphoid cells and arborizing venules. Terms used to define this disease included immunoblastic lymphadenopathy (IBL),' angioimmunoblastic lymphadenopathy with dysproteinemia (AILD),2 and lymphogranulomatosis X (LGRX).3,4 The disease was generally considered to be an abnormal hyperimmune reaction, even though most cases had a rapidly fatal outcome. Immunophenotypical studies have identified the vast majority of proliferating cells as T cells of either CD4 (most commonly) or CD8
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More importantly, cytogenetical studies have disclosed chromosomal abnormalities (most frequently trisomy 3 or 5, or both),8-10 and molecular studies have shown clonal rearrangements of the T-cell receptor genes and, in some instances, immunoglobulin genes or both.11- 16 On the basis of these data, most cases previously diagnosed as AILD are now regarded as belonging to the distinct entity of peripheral T-cell lymphoma of AILD type (AILD-TCL).
In 1976, the screening of 27 cases of lymphoid tissue phoid follicles; (2) in 42% of the cases, the vast majority of infected cells were neoplastic T cells diffusely distributed in the lymph nodes, but infected B cells were also present; and (3) in 32% of the cases, there were only a few infected small lymphoid cells. Detectable LMP was frequent in cases exhibiting patterns 1 and 2. These findings suggest that in AILD-TCL patients, B cells and especially T cells are highly susceptible to a persistent EBV infection, which often leads to a growth advantage of the infected cells. Thus EBV, in conjunction with genetic abnormalities and selective defects of the immune system, might be involved in the pathogenesis of 0 1992 by The American Society of Hematology.
AILD-TCL.
lesions for Epstein-Barr virus (EBV)-DNA using nucleic acid reassociation kinetics led to the detection of one virus-positive case of AILD." Subsequently, there were sporadic publications based on serologic18 and Southern blot a n a l y s i~l~,~ that reported on the presence of EBV in single cases of AILD. In a recent study using the more sensitive polymerase chain reaction (PCR) technique, EBV-DNA was demonstrated in five of eight casesz1 These observations prompted the following questions: How frequently is AILD-TCL associated with EBV when investigated in a larger series? Which cells harbor the EBV genome? Do the EBV-positive cells belong to the neoplastic clone? Is the EBV only a "silent passenger" or is it involved in the pathogenesis of the disease? To clarify these points, a collection of 32 cases of AILD-TCL from three lymphoma research centers (Berlin, Kiel, Oxford) were investigated for the presence of EBV by the demonstration of EBV-DNA in extracted DNA, as well as EBV-encoded small nuclear RNAs (EBER)22s23 and EBV-encoded latent membrane protein (LMP)24-26 in routinely processed tissue sections. This report describes the results obtained with these approaches.
MATERIALS AND METHODS

Specimens and Diagnostic Criteria
Paraffin-embedded lymph node and skin biopsy specimens from 32 patients with the diagnosis of AILD-TCL were selected from the files of the Institute of Pathology, Klinikum Steglitz, Free University, Berlin, Germany, from the Lymph Node Registry, University of Kiel, Germany, and from the Department of Pathology, University of Oxford, John Radcliffe Hospital, Oxford, UK. Serological data as to previous or current EBV infection were only available for cases 3, 9, 10, 11, 23, and 30. These sera contained antibodies against the nuclear antigen of EBV (EBNA), as well as antibodies of IgG isotype against the viral capsid antigen (VCA). Antibodies of IgM isotype against VCA were not observed. The Paul-Bunnell test was negative in all of these cases. Multiple, small axillary lymph nodes removed from 12 patients during the course of mastectomy were used as controls. Histologically, they displayed no signs of activation and are therefore referred to as "normal lymph nodes."
Four-micrometer sections were cut and stained with hematoxylin 
Immunohistology
The bound antibodies were made visible by using the alkaline phosphatase anti-alkaline phosphatase (APAAP) method accord- 
PCR
Ten-micrometer thick paraffin sections were cut from each specimen under conditions preventing DNA cross-contamination. Sections were dewaxed in xylol, precipitated with ethanol, and digested overnight with proteinase K (1 p,g/p,L) at 37°C. One tenth of the digested material was used for amplification after boiling for 15 minutes. PCR was performed in a thermocycler (BioMed 60, BioMed, Theres, Germany) using AmpliTaq (Perkin Elmer-Cetus, Nonvalk, CT) for 40 cycles as previously d e s~r i b e d .~~ For reamplification, 1% of the volume of the first round of amplification was submitted to another 40 rounds of PCR using a set of nested primers (see Table 2 for list of primers used). The optimal concentration of MgC12 for each pair of primers was empirically determined. Ten to twenty microliters of the PCR product was examined with a 2% ethidium-bromide-stained agarose gel for the presence of appropriate bands, blotted on nylon membranes30 (Hybond N, Amersham, Germany), and hybridized with a 32P terminal-transferase-labeled internal oligonucleotide. The positive controls used for each stage of experimentation were the Namalwa cell line harboring one to two copies of EBV," as well as an EBV-positive case of Hodgkin's disease (HD). The negative controls were the EBV-negative cell line HUT10232 and DNAnegative samples (data not shown). The amplification of a section of the B-globin gene served to determine the amplifiability of extracted DNA (Table 2 ). The sensitivity of the PCR approach was determined by an experiment using serial dilutions of Namalwa cell-line DNA, in which only a single copy viral genome could be detected (not shown).
In Situ Hybridization
Plasmids pJJJl and pJJJ2 containing EBERl and EBER2, kindly donated by Dr J. Arrand, Manchester, UK,33 were linearized before in vitro transcription with a combination of T3 or T7 RNA polymerases34 (Bethesda Research Laboratories, Gaithersburg, MD) and 3sS-UTP or digoxigenin (DIG)-UTP.
Hybridization protocol. Hybridization was performed according to established protocols35 on paraffin-embedded tissue sections with either radioactive (35S) or nonisotopic (DIG) labeled in vitro transcribed sense and antisense EBER probes. To increase the sensitivity of in situ hybridization (ISH), a mixture of EBERl and EBER2 antisense probes was applied. A cocktail of the sense Plasmids and probes. For personal use only. on October 25, 2017. by guest www.bloodjournal.org From 
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control probes was also used. After dewaxing with xylene and digestion with proteinase K (500 pglmL), the slides were incubated for 12 hours at 37"Cwith a hybridization solution containing either 1.2 x lo7 cpmlmL of 3sS-labeled or 1 ng of DIG-labeled EBER cocktail per section. After washing in 50% formamid and RNAse A treatment, immobilized radioactive probes were detected by dipping the slides into a 1:2 solution of llford G5 (Ilford, Mobberly. UK) emulsion, followed by exposure for 3 to IO days at 4°C. The slides were then developed and counterstained. An immunologic detection was performed in the case of DIG-labeling. Briefly, the washed slides were incubated with a DIG-specific phosphatase-conjugated Fab fragment and developed with Naphtolas-biphosphate and New Fuchsin (Merck, Darmstadt, Germany)." All steps comprising pretreatment of the slides and hybridization were performed under conditions avoiding RNAse contamination.
To demonstrate the RNA origin of our targets, an RNAse predigestion step was introduced for several cases, resulting in complete disappearance of the signal. Additional ISH with a cocktail of labeled unrelated oligonucleotides on several cases did not lead to any cross-reactivity. Furthermore, no hybridization signal was detected using the EBER sense probes. Sense and antisense probes were checked for their suitability on several EBER-positive and -negative cell lines. The case that was negative for EBER-ISH (case 32) was hybridized with an oligo(dT) primer to ascertain the presence of tissue RNA.
For double labeling, the immunohistologic demonstration of T-cell-specific or characteristic (B-FI and CD45RO). B-cell-specific (CD20) and FDC-characteristic (CD21) antigens was performed before ISH under RNAse-free conditions. In specific, the APAAP technique was used to visualize the detection of the antigens before the application of %-labeled EBER probes, whereas the ABC system was applied in the case of DIG-labeled EBER probes.
Double labeling.
RESULTS
EBV-DNA Detection by PCR
In 12 of the 32 cases of AILD-TCL and 2 of the 12 normal lymphoid tissue samples, the extracted DNA was not amplifiable as shown by the nonappearance of a p-globinspecific band after amplification and reamplification with appropriate primers. In 19 of the remaining 20 AILD-TCL cases, PCR analysis showed EBV-specific sequences (Table  3 ; Fig 1) . In contrast, EBV-specific DNA was demonstrable with the same technique in only 2 of the remaining 10 normal lymphoid tissue samples.
Detection of EBER by ISH
Both radioactive and nonradioactive antisense probes specific for EBER were applied and gave identical results: EBV-infected cells were demonstrable in all but 1 of the 32 AILD-TCL cases (see Table 3 ), as well as in 3 of the 12 normal lymphoid tissue samples.
The comparison of these data with the PCR results showed that the latter data were congruent with the findings of EBER-ISH in all but one instance. In this one exception (case no. 30), EBER-ISH detected only 16 labeled cells in the whole section.
Both the radioactive and nonradioactive EBER-specific probes were suitable for the determination of the overall frequency and distribution of EBV-infected cells. The nonradioactive probes proved to be superior for the morpho- logic evaluation of the EBV-infected cells. With the latter reagents, it could be clearly shown that only lymphoid cells were EBV-positive. All other cell types, including granulocytes, macrophages, endothelial cells, fibrocytes, and plasma cells, were EBV-negative. To identify the lineage allocation of the EBV-infected lymphoid cells, the EBER-ISH labeling was compared with the immunohistological staining reactions obtained on serial sections using the MoAbs listed in Table 1 . Three patterns of EBV-infection were distinguished: (1) A nodular distribution of EBER-positive lymphoid cells predominantly located in the remnants of lymphoid follicles in 8 of 31 cases (Fig 2A) . The majority of these cells exhibited the morphology of immunoblasts with large oval, round, or slightly lobated nuclei and usually a centrally located, prominent nucleolus (Fig 2C) . In several specimens, some EBER-positive cells displayed one or two large nuclei, similar to small-sized variants of HD and Reed-Stemberg (RS) cells (Fig 2C, insert) . In addition, EBER signals were observed in medium-sized cellular elements showing the morphology of proliferating (neoplastic) T cells. (2) A diffuse distribution of many small, medium, and large EBER-positive lymphoid cells in 13 of 31 cases (Fig 3A) . cases (Fig 4) These cells were small and possessed a round or slightly irregularly shaped nucleus, resembling the m asional EBER-positive lymphoid cells occurring in 3 of 12 normal lymphoid tissue samples (Fig 5) .
Double Labeling for EBER and Lineage Markers
All AILD-TCL cases were analyzed using a combination of labeling with nonisotopic EBER probes and immunohistology. Radioactively labeled EBER probes were applied in six cases, two of which were of EBV infection pattern 1 and four of EBV infection pattern 2. Both approaches produced congruent results. The majority of EBER-positive, immunoblast-like cells of the cases showing infection pattern 1 reacted with L26, confirming the B a l l nature of most of these cells (Fig 2B) . The majority of the EBER-positive small, medium, and large cells, as well as many of mitosis present in the cases showing infection pattern 2, were reactive with the MoAbs pF1 and/or UCHL1, hence verifying their T-cell nature (Fig 3B) . In addition, several of the immunoblast-like EBER-positive cells observed in this ed with L26. The single EBER-positive lymphocytes present in the cases showing infection pattern 3 were reactive with either MoAbs pF1 and/or UCHLl or with L26, indicating their T-or B-cell nature (Fig 4, insert) . Double labeling for EBER and CD21 did not lead to a colocalization of the labeling in any of the cases studied, which means that all of the CD21-positive cells, including all FDC, were not infected by EBV.
Detection of EBV-Encoded LMP
The cocktail of four MoAbs directed against different epitopes on the LMP led to the staining of lymphoid cells in 17 of the 32 AILD-TCL. The number of LMP-positive cells was, in all instances, less than the number of EBERpositive cells. LMP was demonstrated on the cell membrane, usually in a patchy distribution, and, in addition, in the cytoplasm. The intensity of the LMP staining varied considerably both within the same case and between cases. The comparison of the LMP staining with the three EBV infection patterns seen with the EBER-ISH led to the following findings: Of the eight AILD-TCL cases displaying infection pattern 1, five contained LMP-positive cells. In four cases, the nodular distribution of the LMP-positive cells was similar to that of the EBER-positive cells, which had the morphology of B immunoblasts and, occasionally, that of binucleated RS cells (Fig 2D) . In the fifth case, the nonappearance of a p-globin band), whereas the applicaThere were no LMP-positive cells detectable in the 12 tion of EBER-ISH produced clearly specific signals in these normal lymphoid tissue samples, including those that concases. tained EBER-positive cells.
When compared with normal lymphoid tissue, it became evident that EBV is more frequently present in AILD-TCL (97%) than in nondiseased lymphoid tissue (25%), which suggests a strong involvement of EBV in the pathogenesis of AILD-TCL. To assess the possible role of EBV in AILD-TCL, the number and identity of EBV-infected cells
DISCUSSION
The data presented here indicate a strong association of AILD-TCL with EBV (97% of cases studied). This evalua- For personal use only. on October 25, 2017 . by guest www.bloodjournal.org From were investigated. In these experiments, the nonradioactive EBER-specific probes proved to be ideal for the morphologic evaluation of the infected cells, whereas ISH with radioactive EBER-specific probes could be well combined with immunohistologic labeling for the determination of the antigenic profile of the infected cells. Through the correlation of the ISH results with morphology and immunohistology, three patterns of EBV-infection were observed (1) predominant EBV infection of large immunoblast-like B cells nodularly distributed in the area of residual lymphoid follicle and minor infection of neoplastic T cells (8/31 cases); (2) predominant EBV infection of many small, medium, and large neoplastic T cells, including those in division, and minor infection of B cells (13/31 cases); and (3) EBV infection of occasional small lymphoid cells (10/31 cases).
LMP was detectable in all three infection pattern groups, with a predominance in the cases of groups 1 and 2. This indicates the transcriptional and translational activity of EBV genes in AILD-TCL in contrast to normal lymphoid tissue, in which the EBV-positive cells were consistently LMP-negative. LMP expression of the EBV-infected cells in AILD-TCL appears to be relevant, as it has already been demonstrated that, in vitro, LMP has transforming potentia137-39 and can prolong cell survival (probably by blockage of programmed cell death through induction of bcl-2 expression) . 40 The predominant infection of B cells in the nodularly EBV-positive cases and the predominant infection of T cells in the diffusely EBV-positive cases was confirmed by double labeling for EBER and lineage markers performed on all AILD-TCL cases. The pathway of B-and T-cell infection by EBV in AILD-TCL is unclear, as cells harboring EBV expressed no detectable levels of the EBVreceptor antigen molecule CD21.41-44 Interestingly, the proliferated FDC also did not contain any detectable EBV, although the EBV-receptor molecule CD21 was expressed-as in normal and other le~ions~~-in all instances at a high density.
The EBV infection of two cell lineages would appear to be unique to AILD-TCL, as this has not yet been reported for other malignancies. This may reflect the differences in the chromosomal aberrations and the configuration of antigen receptor genes between AILD-TCL and other malignant lymphomas. In AILD-TCL, simultaneous rearrangements of T-cell receptor and immunoglobulin genes can be found in a number of instances. 16 Over the course of time, rearrangements disappeared and were occasionally replaced by new ones.15 The frequent presence of karyotypically unrelated abnormal clones and/or cells with nonclonal chromosomal abnormalities and a large proportion of normal mitotic cells, as well as a high incidence of trisomy 3 and 5, have been r e p~r t e d .~.~ Sequential studies have found different patterns of cytogenetic abnormalities, with some clones emerging and predominating over time, and others disappearing completely.8J0 With regard to these findings, it is tempting to speculate that AILD-TCL develops from a persistent EBV-infection during which EBV infects different cell lineages and possibly different cell clones within a cell lineage. Dependent on growth advantage due to genetic alterations and the T-cell reaction against the EBV-infected cells, certain EBV-positive or EBV-negative clones expand or diminish, the result of which is the heterogeneity in the EBV infection patterns described above. Hence, it would appear possible that the disease begins with a deregulated response to antigenic stimulation as a consequence of damage or loss of regulatory cell populations that might otherwise confine EBV infection and limit lymphocyte expansion during immunologic challenge.
A challenge for future research is to elucidate the precise role of EBV in the pathogenesis of AILD-TCL. One possible step in this direction would be the correlation of the EBV detection at the single-cell level with the clinical presentation, appearance, and disappearance of antigen receptor rearrangements and chromosomal abnormalities, mutated oncogenes, and suppressor genes, as well as the course of the disease. Given the rarity of this lymphoma entity, such investigations could only be achieved by a multiinstitutional study.
